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In-Utero Ex-Utero In+Ex Utero In-Utero vs.
Ex-Utero
In-Utero vs.
In+Ex Utero
Ex-Utero vs.
In+Ex Utero
P value P-value P-value
Volume (ml) N¼8,906 N¼6,305 N¼17,527 <0.0001 <0.0001 <0.0001
Median 64.0 54.0 77.1
(Range) (0.5-225.3) (0.2-289.0) (2.0-289.1)
Pre-Processing TNC (x107) N¼6,133 N¼3,514 N¼14,321 < 0.0001 < 0.0001 < 0.0001
Median 108.8 101.0 118.9
(Range) (15.3-1144.8) (13.7-829.5) (9-1359.1)
Post-Processing TNC (x107) N¼4,009 N¼2,124 N¼9,559 < 0.0001 < 0.0001 < 0.0001
Median 113.4 105.4 118.4
(Range) (13.4-602.0) (3.8-459.8) (28.9-679.7)
Post-processing CD34+ cells ( x106) N¼3,857 N¼2,009 N¼9,069 < 0.0001 0.7670 < 0.0001
Median 5.03 4.26 4.93
(Range) (0.36-57.64) (0-53.03) (0.03-63.36)
Microbial Contamination (%) N¼4,051
2.0
N¼2,107
0.5
N¼9,503
2.0
< 0.0001 0.8278 < 0.0001
Table
Correlation of MSKCC post-thaw results with NCBP pre-cryopreservation
CBU and segment evaluation
VCD34+ cells Specimen, Lab Specimen, Lab N R2 p
pre-cryo, NCBP segment, NCBP 68 0.85 <0.0001
segment, NCBP post-thaw, MSKCC 68 0.72 <0.0001
pre-cryo, NCBP post-thaw, MSKCC 68 0.70 <0.0001
CFU Specimen, Lab Specimen, Lab
pre-cryo, NCBP segment, NCBP 43 0.52 <0.001
segment, NCBP post-thaw, MSKCC 63 0.22 <0.001
pre-cryo, NCBP post-thaw, MSKCC 42 0.20 0.0017
v. viable CD34+ cells: N: number of CBU (not all CBU had pre-cryopreser-
vation CFU data).
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Hematopoietic Progenitor Cell (HPC) mobilization should
take into consideration efﬁcacy, predictability, convenience
and cost. Despite many different schemas available, the
optimal growth factor regimen for chemo-mobilization is
still debatable. The standard growth factor used in HPC
mobilization is ﬁlgrastim (G-CSF) 10mcg/kg/day, adminis-
tered subcutaneously. Patients usually receive daily G-CSF
injections after chemotherapy in average of 10 days before
starting apheresis. Medicare patients have to go to hospital
or clinic every day to have their G-CSF injections given. We
retrospectively evaluated our experience with pegylated-
ﬁlgrastim given in conjunction with a subsequent short
course G-CSF in 15 patients (8F/7M) with multiple myeloma
(n¼6) and lymphoma (n¼9) who underwent chemo-growth
factor HPC mobilization for high-dose chemotherapy and
autologous stem cell transplantation. Median age was 68
(52-78). Chemotherapy regimen used for mobilizationwas at
the discretion of the transplant physician and included
cyclophosphamide (n¼2), DV-PACE (n¼5), DHAP (n¼2),
ESHAP (n¼2), EPOCH (n¼2), ICE (n¼1), mostly combined
with Rituximab. We planned ahead of time that chemo-
therapy is completed by the end of the week so that the
patient could spend the weekend at home and receive peg-
ﬁlgrastim at a single ﬁxed dose (6 mg) subcutaneously in the
following week with a median 3 (2-4) days after the last day
of chemotherapy. At the time of recovery when median WBC
was 0.6/mcL (0.1-3.8), daily G-CSF, at a median dose of 6mcg/
kg/day (5-12) was initiated in 5 (4-7) days after the dose of
pegﬁlgrastim. Five patients (33%) received additional Pler-
ixafor. HPC collection was started based on peripheral CD34
count in a median 3 days (1-6) after the initiation of G-CSF
and in 16 days (11-18) after the initial chemotherapy
administration. After 2 days (1-3) of apheresis, all patients
but one had adequate (>2 x 106) CD34+ cells/kg in HPC
product. Median CD34+ cell count on peripheral blood on
day+1 apheresis was 32 (4.6-407) x 106/kg. All patients had
full myeloid recovery and median time to ANC>500 x 3
consecutive days was 11 days (10-18) days. No graft failurewas observed. All patients tolerated the mobilization
regimen well with no serious side effects. Our preliminary
data suggest that single dose pegﬁlgrastim in conjunction
with low dose short course G-CSF can provide satisfactory
HPC mobilization and be considered an alternative conve-
nient growth factor regimen for select patients. A prospec-
tive study is currently underway in our institution.186
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Background: MSKCC analyses have shown that the infused
viable CD34+ cell dose is the critical determinant of neutro-
phil engraftment after CB transplantation (Purtill et al, Blood
2014). However, currently, CD34+ cell viability can only be
obtained on transplant day at unit thaw. Whether testing of
the segment attached to the freezing bag at the Bank prior to
unit release can predict the post-thaw CBU quality/potency
at the transplant center is not established.
Methods: We compared the post-thaw results of 68 NCBP
CBU, AXP-processed, stored in BioArchive freezers, shipped,
and thawed at MSKCC, with their respective segment and
